Drug intelligence / Profile preview

rhTFAM

Development stage: Preclinical
Lead developer: Gencia
Modality: Gene Therapies
Administration: Intravenous, Intraperitoneal

Overview

rhTFAM is a gene therapy product that utilizes a gene therapy approach to deliver the gene for recombinant human mitochondrial transcription factor A to the brain. This aims to increase mitochondrial function and restore memory, addressing cognitive impairment and early Alzheimer's disease. Preclinical research has been conducted in mouse models.

Other names: recombinant human mitochondrial transcription factor A gene therapy

Targets

TFAM (Mitochondrial transcription factor A)

Beyond the preview

Go deeper on rhTFAM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rhTFAM.

Explore the full profile